<DOC>
	<DOCNO>NCT01055392</DOCNO>
	<brief_summary>Lithium salt use treatment psychiatric disorder five decade , mostly mood-stabilizing drug . Recent evidence point inhibition enzyme glycogen synthase kinase-3beta ( GSK3 ) one mechanisms action . The overactivity enzyme implicated pathogenesis Alzheimer 's disease ( AD ) , give involvement mechanism related hyperphosphorylation Tau protein production beta-amyloid peptide . These key event lead respectively formation neurofibrillary tangle senile plaque , neuropathological hallmark disease . Several vitro animal study show inhibition GSK3 lithium agent attenuate pathological process , reinforce notion GSK3 likely target future disease-modifying therapy AD . Indeed , recent study publish group show chronic lithium use associate decrement expect prevalence dementia , sample elderly individual bipolar disorder . To investigate putative neuroprotective effect prospective way , investigator start 24-month randomized , double-blinded control trial lithium prevention dementia sample elderly individual amnestic mild cognitive impairment ( MCI ) , condition associate increase risk development AD . The clinical biological outcome trial include attenuation cognitive deficit , modification certain biological marker disease ( measure cerebrospinal fluid , leukocytes platelet ) . The objective present application enable extension ongoing trial additional 2-year follow-up . A long follow-up ( 48 month ) increase statistical power ascertain primary outcome variable study , particularly con-version MCI Alzheimer 's disease . This warrant consistent conclusion potential lithium treatment prevention dementia , addition well evaluation safety tolerability profile long-term use lithium older individual .</brief_summary>
	<brief_title>Disease-modifying Properties Lithium Neurobiology Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<criteria>patient amnestic mild cognitive impairment ; age : 60 80 yearsold ; sensory deficiency might preclude administration cognitive test ; active major psychiatry disorder ; unstable clinical condition cardiac insufficiency , uncontrolled diabetes mellitus , renal failure ; previous use lithium salt ; concurrent participation clinical trial intervention study ;</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>mild cognitive impairment</keyword>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>Lithium</keyword>
	<keyword>disease-modification</keyword>
	<keyword>cognition</keyword>
	<keyword>early Alzheimer ` disease</keyword>
</DOC>